Key Segments:
By Product
-
Reagents and Assays
-
Instruments
-
Software and AI
By Biomarker Type
-
Genomic Biomarkers
-
Proteomic Biomarkers
-
Metabolomic Biomarkers
-
Others
By Technology
-
Next-Generation Sequencing
-
Immunohistochemistry
-
In Situ Hybridization
-
Spatial Biology Platforms
By Application
-
Oncology
-
Companion Diagnostics
-
Neurology
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Roche, Agilent, Thermo Fisher, Illumina, QIAGEN, NeoGenomics, Bruker Spatial Biology, Bio-Techne, Leica Biosystems, Foundation Medicine, Labcorp, Quest Diagnostics, Bio-Rad, PathAI, 10x Genomics, Caris Life Sciences, Tempus AI, and Visiopharm.
The main opportunities lie in advancing spatial biology platforms toward routine clinical use, and in expanding laboratory infrastructure and distribution partnerships across emerging markets.
The key growth factor is the growing requirement for biomarker-based patient selection alongside new targeted and immuno-oncology drug approvals, reinforced by broader use of multi-gene tissue profiling panels in routine oncology care.
By product, the Reagents and Assays segment dominated the market with approximately 54.00% share in 2025, reflecting its position as the recurring consumable component of every testing workflow.
North America dominated the market with approximately 45.00% share in 2025, supported by a dense concentration of academic medical centers and reference laboratories.
